Sarchi Christopher 4

What Happened
Christopher Sarchi, Chief Commercial Officer of Replimune Group, sold 6,500 shares of REPL in an open-market/private sale on April 2, 2026. The weighted-average sale price was $8.01 (range $8.00–$8.06), for aggregate proceeds of approximately $52,065. This was a sale (not a purchase or option exercise).

Key Details

• Transaction date: 2026-04-02; Transaction type: Sale (S)
• Price: weighted average $8.01; reported range $8.00–$8.06 (report says per-price breakdown can be provided on request)
• Shares sold: 6,500; Proceeds: ~$52,065
• Holdings after sale: beneficial ownership of 151,588 shares (includes restricted stock units)
• Derivatives: holds options to acquire 250,425 shares, of which 142,555 are exercisable as of the report date
• Trading plan: sale executed under a Rule 10b5-1 trading plan adopted December 15, 2025 (footnote indicates plan compliance)
• Timeliness: Form 4 filed Apr 6, 2026 reporting a 4/2/2026 transaction; no late filing indicator shown

Context
Trades under a 10b5-1 plan are prearranged and do not necessarily reflect the insider’s current view of the company; they are commonly used for scheduled liquidity. This filing reports a routine insider sale rather than a purchase or option exercise; investors often treat purchases as stronger signals of insider conviction.